Plant-Derived Agents and Systemic Sclerosis: A Systematic Review of Therapeutic Potential and Molecular Mechanisms
Open Access
- 18 January 2026
- journal article
- review article
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (1) , 97
Abstract
Systemic sclerosis (SSc) is a rare multisystemic autoimmune disease associated with progressive fibrosis, vasculopathy, and immune dysregulation. Despite advances in its management, the disease remains associated with substantial morbidity and mortality, with limited therapeutic options. This systematic review aimed to identify phytocompounds and medicinal plants that had demonstrated efficacy in SSc. A comprehensive literature search was performed in PubMed and ScienceDirect, yielding 7797 records, of which 32 studies met the inclusion criteria. A second search was performed using the SwissTargetPrediction tool to identify new putative molecular targets for these phytocompounds, whose relevance for SSc pathogenesis was verified by a third search in PubMed and ScienceDirect databases. Our search found 24 phytocompouds (e.g., halofunginone, crocetin, and tanshinone IIA) and 5 plant extracts (e.g., caper bush and ciplukan) reported to modulate key pathogenic processes in SSc. These phytochemicals were mainly associated with effects on endothelial to mesenchymal transition, oxidative stress, inflammation, and profibrotic signaling pathways, particularly TGF-β/Smad. The SwissTargetPrediction tool indicated 93 new potential molecular targets of the selected phytochemicals, among which only 41 showed relevance to SSc pathogenesis. In conclusion, available evidence is scarce but promising. Further studies, especially human investigations, are required to clarify clinical efficacy, safety, and potential interactions with drugs used in SSc.Keywords
This publication has 160 references indexed in Scilit:
- Targeting CD13/Aminopeptidase N as a Novel Therapeutic Approach for Scleroderma FibrosisArthritis & Rheumatology, 2024
- Withaferin A attenuates bleomycin‐induced scleroderma by targeting FoxO3a and NF‐κβ signaling: Connecting fibrosis and inflammationBioFactors, 2018
- Endothelial Cells Expressing Endothelial and Mesenchymal Cell Gene Products in Lung Tissue From Patients With Systemic Sclerosis–Associated Interstitial Lung DiseaseArthritis & Rheumatology, 2015
- A Reactive Oxygen Species–Mediated Loop Maintains Increased Expression of NADPH Oxidases 2 and 4 in Skin Fibroblasts From Patients With Systemic SclerosisArthritis & Rheumatology, 2015
- Skin Gene Expression Correlates of Severity of Interstitial Lung Disease in Systemic SclerosisArthritis & Rheumatism, 2013
- Effect of oxidative stress on protein tyrosine phosphatase 1B in scleroderma dermal fibroblastsArthritis & Rheumatism, 2011
- A novel inhibitor of Smad‐dependent transcriptional activation suppresses tissue fibrosis in mouse models of systemic sclerosisArthritis & Rheumatism, 2009
- The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosisArthritis & Rheumatism, 2009
- Oxidative stress in scleroderma: Maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathwayArthritis & Rheumatism, 2001
- Evidence of 5-lipoxygenase overexpression in the skin of patients with systemic sclerosis: A newly identified pathway to skin inflammation in systemic sclerosisArthritis & Rheumatism, 2001